SLC1A3 is a novel prognostic biomarker associated with immunity and EMT in hepatocellular carcinoma
SLC1A3 functions as a cancer-promoting factor contributing to poor HCC prognosis by affecting immune cell infiltration and regulating the EMT process. Elevated SLC1A3 expression may also serve as a predictor of treatment response to specific antitumor drugs.
Authors
- Renhou Zhi (ORCID: https://orcid.org/0000-0002-8061-842X)
- Fan Fan (ORCID: https://orcid.org/0000-0003-3986-5303)
Institutions
- Shanxi Medical University (CN)
- Shanxi Provincial Cancer Hospital (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- Shanxi Academy of Medical Sciences (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1007/s12672-024-01561-5
- Citations
- 4
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 1.13